Bionime Corporation (4737.TW)
TWD 66.0
(-0.9%)
TWD 66.0
(-0.9%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 2.81 Billion TWD | 24.09% |
| 2022 | 2.27 Billion TWD | 11.75% |
| 2021 | 2.03 Billion TWD | 1.23% |
| 2020 | 2 Billion TWD | 8.77% |
| 2019 | 1.84 Billion TWD | -12.92% |
| 2018 | 2.11 Billion TWD | 13.96% |
| 2017 | 1.85 Billion TWD | 18.9% |
| 2016 | 1.56 Billion TWD | -7.94% |
| 2015 | 1.69 Billion TWD | -41.1% |
| 2014 | 2.88 Billion TWD | -9.45% |
| 2013 | 3.18 Billion TWD | 28.07% |
| 2012 | 2.48 Billion TWD | 60.68% |
| 2011 | 1.54 Billion TWD | 1297.43% |
| 2010 | 110.75 Million TWD | 8.72% |
| 2009 | 101.86 Million TWD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 2.82 Billion TWD | 1.7% |
| 2024 Q1 | 2.77 Billion TWD | -1.49% |
| 2023 Q3 | 2.65 Billion TWD | 9.72% |
| 2023 FY | 2.81 Billion TWD | 24.09% |
| 2023 Q1 | 2.29 Billion TWD | 1.17% |
| 2023 Q2 | 2.42 Billion TWD | 5.52% |
| 2023 Q4 | 2.81 Billion TWD | 5.94% |
| 2022 Q3 | 2.32 Billion TWD | 2.18% |
| 2022 FY | 2.27 Billion TWD | 11.75% |
| 2022 Q4 | 2.27 Billion TWD | -2.38% |
| 2022 Q2 | 2.27 Billion TWD | 0.44% |
| 2022 Q1 | 2.26 Billion TWD | 11.54% |
| 2021 Q1 | 1.98 Billion TWD | -0.96% |
| 2021 FY | 2.03 Billion TWD | 1.23% |
| 2021 Q3 | 2.06 Billion TWD | 6.0% |
| 2021 Q4 | 2.03 Billion TWD | -1.45% |
| 2021 Q2 | 1.94 Billion TWD | -2.16% |
| 2020 Q1 | 1.72 Billion TWD | -6.25% |
| 2020 Q4 | 2 Billion TWD | -3.03% |
| 2020 FY | 2 Billion TWD | 8.77% |
| 2020 Q2 | 1.92 Billion TWD | 11.35% |
| 2020 Q3 | 2.06 Billion TWD | 7.46% |
| 2019 Q2 | 1.83 Billion TWD | -9.21% |
| 2019 Q4 | 1.84 Billion TWD | -7.29% |
| 2019 FY | 1.84 Billion TWD | -12.92% |
| 2019 Q1 | 2.02 Billion TWD | -4.58% |
| 2019 Q3 | 1.99 Billion TWD | 8.42% |
| 2018 Q4 | 2.11 Billion TWD | 11.77% |
| 2018 FY | 2.11 Billion TWD | 13.96% |
| 2018 Q3 | 1.89 Billion TWD | 20.67% |
| 2018 Q2 | 1.57 Billion TWD | -12.45% |
| 2018 Q1 | 1.79 Billion TWD | -3.5% |
| 2017 Q3 | 2.03 Billion TWD | 21.93% |
| 2017 Q2 | 1.67 Billion TWD | 14.43% |
| 2017 Q1 | 1.46 Billion TWD | -6.58% |
| 2017 FY | 1.85 Billion TWD | 18.9% |
| 2017 Q4 | 1.85 Billion TWD | -8.78% |
| 2016 Q3 | 1.47 Billion TWD | -7.31% |
| 2016 Q4 | 1.56 Billion TWD | 5.95% |
| 2016 FY | 1.56 Billion TWD | -7.94% |
| 2016 Q1 | 1.54 Billion TWD | -9.05% |
| 2016 Q2 | 1.59 Billion TWD | 3.07% |
| 2015 Q1 | 2.32 Billion TWD | -19.47% |
| 2015 Q2 | 2.35 Billion TWD | 1.46% |
| 2015 Q3 | 2.4 Billion TWD | 2.07% |
| 2015 FY | 1.69 Billion TWD | -41.1% |
| 2015 Q4 | 1.69 Billion TWD | -29.38% |
| 2014 Q3 | 3.08 Billion TWD | 1.14% |
| 2014 Q1 | 3.02 Billion TWD | -5.09% |
| 2014 FY | 2.88 Billion TWD | -9.45% |
| 2014 Q4 | 2.88 Billion TWD | -6.59% |
| 2014 Q2 | 3.05 Billion TWD | 0.98% |
| 2013 FY | 3.18 Billion TWD | 28.07% |
| 2013 Q3 | 2.75 Billion TWD | 6.11% |
| 2013 Q4 | 3.18 Billion TWD | 15.63% |
| 2013 Q1 | 2.57 Billion TWD | 3.73% |
| 2013 Q2 | 2.59 Billion TWD | 0.63% |
| 2012 Q1 | 2.35 Billion TWD | 51.96% |
| 2012 FY | 2.48 Billion TWD | 60.68% |
| 2012 Q4 | 2.48 Billion TWD | 0.66% |
| 2012 Q3 | 2.47 Billion TWD | 4.77% |
| 2012 Q2 | 2.35 Billion TWD | 0.26% |
| 2011 Q1 | 320.71 Million TWD | 189.58% |
| 2011 Q4 | 1.54 Billion TWD | -11.72% |
| 2011 FY | 1.54 Billion TWD | 1297.43% |
| 2011 Q3 | 1.75 Billion TWD | 300.84% |
| 2011 Q2 | 437.36 Million TWD | 36.37% |
| 2010 FY | 110.75 Million TWD | 8.72% |
| 2010 Q4 | 110.75 Million TWD | 0.0% |
| 2009 FY | 101.86 Million TWD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Nang Kuang Pharmaceutical Co., Ltd. | 605.96 Million TWD | -364.913% |
| Maxigen Biotech Inc. | 50 Thousand TWD | -5634292.0% |
| SciVision Biotech Inc. | 347.91 Million TWD | -709.742% |
| Pegavision Corporation | 1.56 Billion TWD | -80.125% |
| Visco Vision Inc. | 1.08 Billion TWD | -159.942% |